Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Kim HR, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, Kim H, Pyo KH, Yun MR, Park HJ, Han JY, Youn HA, Ahn MJ, Paik S, Kim TM, Cho BC.
Kim HR, et al. Among authors: ahn mj.
Ann Oncol. 2017 Jun 1;28(6):1250-1259. doi: 10.1093/annonc/mdx098.
Ann Oncol. 2017.
PMID: 28460066
Free article.